Detalhe da pesquisa
1.
The Single Toxin Origin of Alzheimer's Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention.
Int J Mol Sci
; 25(5)2024 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38473975
2.
Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression.
Int J Mol Sci
; 22(12)2021 Jun 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34198582
3.
The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis.
Alzheimers Dement
; 16(11): 1553-1560, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31706733
4.
Botulinum toxin type E associated with reduced itch and pain during wound healing and acute scar formation following excision and linear repair on the forehead: A randomized controlled trial.
J Am Acad Dermatol
; 89(6): 1317-1319, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37666427
5.
Neuropsychiatric symptom clusters targeted for treatment at earlier versus later stages of dementia.
Int J Geriatr Psychiatry
; 30(4): 357-67, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24798635
6.
Analysis of Cerebrospinal Fluid, Plasma ß-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer's Disease Using Quantitative Systems Pharmacology Model.
Drugs
; 2024 Jun 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38902572
7.
Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer's Disease.
Drugs
; 2024 Jun 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38902571
8.
Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease.
Alzheimers Dement
; 9(2): 123-131.e1, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23411394
9.
The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier).
Alzheimers Dement
; 9(2): 189-98, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23062850
10.
Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.
Alzheimers Res Ther
; 12(1): 95, 2020 08 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32787971
11.
APOE ε4/ε4 homozygotes with early Alzheimer's disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline.
Alzheimers Dement (N Y)
; 6(1): e12117, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33304988
12.
Safety and Efficacy of EB-001, a Novel Type E Botulinum Toxin, in Subjects with Glabellar Frown Lines: Results of a Phase 2, Randomized, Placebo-Controlled, Ascending-Dose Study.
Plast Reconstr Surg
; 142(6): 847e-855e, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30489516
13.
Correction to: Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain.
CNS Drugs
; 32(12): 1185, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30421245
14.
Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain.
CNS Drugs
; 32(9): 849-861, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30076539
15.
Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
Clin Pharmacokinet
; 57(3): 315-333, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29063518
16.
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral ELND005 (scyllo-Inositol) in Young Adults with Down Syndrome without Dementia.
J Alzheimers Dis
; 58(2): 401-411, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28453471
17.
Pharmacokinetic Profile of Orally Administered Scyllo-Inositol (Elnd005) in Plasma, Cerebrospinal Fluid and Brain, and Corresponding Effect on Amyloid-Beta in Healthy Subjects.
Clin Pharmacol Drug Dev
; 2(2): 186-94, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-27121673